EUVIMEDOdkrijte EUVIMED
Crossref

Eltrombopag for the treatment of chronic immune thrombocytopenia

Stavroula Tsiara, Nichola Cooper

Clinical Investigation · 2011

DOI: 10.4155/cli.10.23 ↗

At a glance

Journal article in Clinical Investigation, 2011. Written by Stavroula Tsiara and 1 co-authors. Cited 2 times so far (Crossref); 54 references.

AbstraktBibliografické údajeCiteRelated studies

Abstract (original language)

Immune thrombocytopenic purpura (ITP) is an immune-mediated platelet disorder. Although early studies suggest that the main feature is antiplatelet antibody production and increased platelet clearance, more recent evidence implies that defective platelet production and suppressed maturation and differentiation of megakaryocytes also occurs. In this context, second-generation thrombopoietic agents, romiplostim and eltrombopag, have been developed for patients with chronic resistant/relapsing ITP. Eltrombopag has shown safety and efficacy in three double-blind randomized placebo-controlled multicenter studies. In these studies, a dose-dependent platelet increase to over 50 × 109/l was achieved in 58–60% of the patients. Bleeding episodes were significantly less in patients receiving eltrombopag relative to placebo. Platelet counts returned to baseline within 2 weeks of discontinuation of eltrombopag. Adverse events were mild and similar in eltrombopag- and placebo-treated groups. Transaminases increased, an...

Cite

APA

Tsiara, S., & Cooper, N. (2011). Eltrombopag for the treatment of chronic immune thrombocytopenia. Clinical Investigation. https://doi.org/10.4155/cli.10.23

Vancouver

Tsiara S, Cooper N. Eltrombopag for the treatment of chronic immune thrombocytopenia. Clinical Investigation. 2011. doi:10.4155/cli.10.23

BibTeX
@article{Tsiara2011,
  author = {Tsiara, Stavroula and Cooper, Nichola},
  title = {Eltrombopag for the treatment of chronic immune thrombocytopenia},
  journal = {Clinical Investigation},
  year = {2011},
  doi = {10.4155/cli.10.23}
}
Start for free →